-10.8%
CTSH vs MRNA
+511.3%
-522.1%
-54.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.6% | -2.2% | -1.4% | -3.5% |
| 7D | -2.7% | +5.5% | -8.2% | -2.9% |
| 30D | +12.4% | +158.7% | -146.4% | +6.4% |
| 3M | +17.4% | +182.1% | -164.8% | +10.4% |
| 6M | -3.1% | +151.8% | -154.9% | -7.9% |
| YTD | -23.6% | +393.6% | -417.1% | -32.4% |
| 1Y | -10.8% | +499.5% | -510.3% | -24.7% |
| All | -10.8% | +511.3% | -522.1% | -24.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling